Warning: fopen(/home/virtual/epih/journal/upload/ip_log/ip_log_2024-05.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 95 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 96 Cancer risk based on alcohol consumption levels: a comprehensive systematic review and meta-analysis
Skip Navigation
Skip to contents

Epidemiol Health : Epidemiology and Health



Page Path
HOME > Epidemiol Health > Volume 45; 2023 > Article
Special Article
Cancer risk based on alcohol consumption levels: a comprehensive systematic review and meta-analysis
Seunghee Jun1,2*orcid, Hyunjin Park1,2*orcid, Ui-Jeong Kim1orcid, Eun Jeong Choi1,3orcid, Hye Ah Lee4orcid, Bomi Park5orcid, Soon Young Lee6orcid, Sun Ha Jee7orcid, Hyesook Park1,2orcid
Epidemiol Health 2023;45:e2023092.
DOI: https://doi.org/10.4178/epih.e2023092
Published online: October 16, 2023

1Department of Preventive Medicine, Ewha Womans University College of Medicine, Seoul, Korea

2Graduate Program in System Health Science and Engineering, Ewha Womans University College of Medicine, Seoul, Korea

3National Cancer Control Institute, National Cancer Center, Goyang, Korea

4Clinical Trial Center, Ewha Womans University Mokdong Hospital, Seoul, Korea

5Department of Preventive Medicine, Chung-Ang University College of Medicine, Seoul, Korea

6Department of Preventive Medicine and Public Health, Ajou University School of Medicine, Suwon, Korea

7Institute for Health Promotion, Department of Epidemiology and Health Promotion, Graduate School of Public Health, Yonsei University, Seoul, Korea

Correspondence: Hyesook Park Department of Preventive Medicine, Ewha Womans University College of Medicine, 25 Magokdong-ro 2-gil, Gangseo-gu, Seoul 07804, Korea E-mail: hpark@ewha.ac.kr
*Jun & Park contributed equally to this work as joint first authors.
• Received: July 7, 2023   • Accepted: September 13, 2023

© 2023, Korean Society of Epidemiology

This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 374 Download
  • 2 Web of Science
  • 1 Crossref
  • 1 Scopus
    Alcohol consumption is a well-established risk factor for cancer. Despite extensive research into the relationship between alcohol consumption and cancer risk, the effect of light alcohol consumption on cancer risk remains a topic of debate. To contribute to this discourse, we conducted a comprehensive systematic review and meta-analysis.
    Our systematic review aimed to investigate the associations between different levels of alcohol consumption and the risk of several cancer types. We focused on analyzing prospective associations using data from 139 cohort studies. Among them, 106 studies were included in the meta-analysis after a quantitative synthesis.
    Our analysis did not find a significant association between light alcohol consumption and all-cause cancer risk (relative risk, 1.02; 95% confidence interval, 0.99 to 1.04), but we observed a dose-response relationship. Light alcohol consumption was significantly associated with higher risks of esophageal, colorectal, and breast cancers. Light to moderate drinking was associated with elevated risks of esophageal, colorectal, laryngeal, and breast cancers. Heavy drinking was also found to contribute to the risk of stomach, liver, pancreas, and prostate cancers, thereby increasing the risk of almost all types of cancer. Additionally, females generally had lower cancer risks compared to males.
    Our findings highlight that cancer risks extend beyond heavy alcohol consumption to include light alcohol consumption as well. These findings suggest that there is no safe level of alcohol consumption associated with cancer risk. Our results underscore the importance of public health interventions addressing alcohol consumption to mitigate cancer risks.
Cancer is the second leading cause of death globally, accounting for almost 10 million deaths in 2020 [1]. Alcohol consumption causes a range of diseases, including cancer [2]. In 1988, the International Agency for Research on Cancer (IARC) classified alcohol as a Group 1 human carcinogen [3]. The IARC also lists alcohol as a cause of breast, colorectal, laryngeal, liver, esophageal, oral, and pharyngeal cancers [4,5]. According to the Global Burden of Cancer in 2020 Attributable to Alcohol Consumption study, approximately 741,300 cancer cases (95% uncertainty interval [UI], 558,500 to 951,200; population-attributable fraction, 4.1% [95% UI, 3.1 to 5.3]) were attributable to alcohol consumption [6].
The association between alcohol consumption and the risk of cancer death follows a J-shaped pattern, where heavy drinkers exhibit a higher cancer mortality rate than moderate drinkers [7,8]. Cohort studies have shown that even a small amount of alcohol consumption is associated with a heightened risk of cancer and death [9,10]. Furthermore, a meta-analysis reported that light alcohol consumption (1 drink per day, < 12 g alcohol) was linked to increased risks of esophageal (30%), oropharyngeal (17%), liver (8%), colon (7%), and breast (5%) cancers [11]. Furthermore, among female, light alcohol consumption was associated with 20% excess risks of breast and colorectal cancers [12].
Given the evidence linking alcohol consumption with cancer, various countries have established guidelines on alcohol intake [13,14]. For instance, the IARC’s third edition of the European Code Against Cancer (ECAC) recommended a limit of “no more than two drinks a day for male and one drink per day for female” [15]. The fourth edition now recommends, “If you drink alcohol of any type, limit your intake. Not drinking alcohol is better for cancer prevention” [16]. Korea has similarly revised cancer prevention guidelines, shifting from ‘limiting alcohol to 1-2 drinks a day’ to virtually abstaining from drinking [17].
Critics have argued that the meta-analysis by Bagnardi et al. [11], which was central to the fourth edition of the ECAC guidelines [16], may have produced inaccurate recommendations [18]. In particular, it has been pointed out that this study failed to take into consideration the differences between case-control and cohort study design, which resulted in an incorrect conclusion being drawn from a combination of findings from both study types [18,19]. The study of Choi et al. [19] supported the link between light alcohol consumption and an increased risk of cancer. However, it should be noted that their study focused only on light drinking patterns and therefore could not determine the effects of varying alcohol consumption levels. As most existing research has focused on specific levels of alcohol consumption or specific cancer types, there is still a lack of studies establishing the risk relationship between different drinking levels and various cancer types.
Our study sought to investigate the association between light to heavy alcohol intake and cancer risk, unlike many studies that have focused solely on specific alcohol consumption levels. We also concentrated on a variety of cancer types identified as alcohol-related carcinomas by the IARC [20]. To ensure our studies drew from the most recent evidence, we integrated data from the Korean Cancer Prevention Study-II and the Korean Genome Epidemiology Study Biobank (Pooled Korean Biobank) [21]. This approach allowed us to encompass a broader range of literature than previous meta-analyses, thereby enabling us to present up-to-date findings.
We conducted the study following the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines (Figure 1). A systematic literature search was conducted using 5 databases (Embase, Cochrane Library, PubMed, Scopus, and Web of Science) to identify original articles published up to July 2021. The search was performed using relevant keywords such as “alcohol,” “alcohol drinking,” “neoplasm,” “cancer,” “carcinoma,” and “cohort.” Only studies published in English were considered. In addition to the database search, the references of the retrieved articles were manually screened to identify any additional relevant studies.
Two authors (SJ and HjP) independently reviewed the titles and abstracts of the retrieved articles based on pre-set eligibility criteria. The full texts of the remaining articles after the initial screening were assessed by both researchers independently for final inclusion. Any inconsistencies between the 2 researchers were resolved through a consensus meeting with other authors (HAL BP, SYL and HsP).
The inclusion criteria for the meta-analysis were as follows: (1) studies focusing on esophageal, stomach, liver, pancreatic, colorectal, larynx, lung, thyroid, breast, and prostate cancers; (2) original cohort studies (excluding abstracts, letters, reviews, and meta-analyses); (3) studies reporting quantitative findings regarding the relationship between alcohol consumption and the risk of cancer as hazard ratios (HRs), relative risks (RRs), or odds ratios (ORs) for alcohol drinkers compared to non-drinkers or occasional drinkers; (4) studies providing the standard error or confidence interval (CI) of the risk estimate or sufficient data for their calculation; and (5) studies with the full text accessible. If multiple articles reported results from the same study, the most recent or complete article was included. Studies that evaluated specific types of alcoholic beverages only were excluded to avoid potential confounding.
Data extraction included information such as first author, year of publication, country, follow-up duration, cohort size and cases, sex, alcohol consumption level, OR/RR/HR and 95% CI, confounders considered, and outcomes (cancer incidence or death). If available, data were evaluated by sex. The methodological quality of the included studies was assessed independently by 2 authors (SJ and HjP) using the Newcastle-Ottawa Scale (NOS), with a higher score indicating higher methodological quality (NOS score ≥ 7 considered high-quality). Any disagreements or uncertainties were resolved through discussion to reach a consensus.
For the purpose of analysis, alcohol consumption was categorized into 4 levels: light (0.01-12.4 g/day), light to moderate (12.5-24.9 g/day), moderate to high (25.0-49.9 g/day), and heavy (≥ 50.0 g/day). Various units of alcohol consumption (grams, milliliters, ounces, or number of drinks) reported in the studies were converted to grams per day using the following conversion factors: 0.8 g/mL, 28 g/oz, and 12 g/glass [22]. In studies that provided cancer risk based on categories of alcohol intake, the median value of each category was used for analysis [23].
A meta-analysis was performed to estimate the pooled RR of cancer for each alcohol consumption level, except for laryngeal cancer due to insufficient data. Since cancer is a rare disease, the OR, RR, and HR were assumed to be comparable estimates of the RR. The analysis included risk estimates that were adjusted for confounding factors, and if adjusted values were unavailable, crude values were used. We computed pooled RR estimates for the reported cancer risk compared to non-drinkers by alcohol consumption level. All analyses were performed without distinguishing between incident cancer and death.
Forest plots were used to identify heterogeneity between studies, and the degree of heterogeneity was quantified using the I2 statistic, with low (< 25%), medium (25 to ≤ 75%), and high (> 75%) [24] levels of heterogeneity considered. A fixed-effects model was used in most cases; however, a random-effects model was used if there was high heterogeneity between studies. To assess the dose-response association between alcohol consumption and cancer risk, a dose-response meta-analysis was conducted. The linearity and non-linearity of associations were evaluated [25]. Publication bias was evaluated using funnel plots and Egger’s regression asymmetry test [26].
The statistical analysis was carried out using R studio version 4.2.1 and the “metafor” package in R software (https://cran.r-project.org/). The results of 2-sided tests were considered statistically significant when p< 0.05.
Ethics statement
This study is not required to ethical approval since it was based on published articles.
We conducted a comprehensive study selection process, which is presented in Figure 1. Initially, we identified a total of 126,135 articles, including systematic review papers, through a literature search. After excluding 33,580 duplicates articles, we reviewed the titles and abstracts of the remaining 92,555 articles, resulting in the exclusion of 91,701 irrelevant articles. After reviewing the full text of 854 articles, 715 were excluded because they had insufficient data (n=169), were published in a language other than English (n=8), were gray literature (n=27), had an inaccessible full text (n=150), dealt with cancer types other than those under investigation (n = 105), and had case–control or other study designs (n=256). The systematic review included a total of 139 papers. Among these, 34 articles were considered unsuitable for assessing cancer risk associated with alcohol consumption and were subsequently excluded. The final meta-analysis comprised 106 articles, which included an additional key study for a comprehensive analysis. The reference list categorized by cancer type is shown in Supplementary Marterials 1 and 2 provides a summary of confounding factors stratified by cancer type, based on the selected literature.
Table 1 summarizes the characteristics of the studies included in the meta-analysis by cancer type, excluding the key study. Of the included articles, 73 were published before 2010, while 32 were published after 2010. These studies were conducted in the Americas (n=43), Asia (n=32), and Europe or Australia (n=30). The cohort size ranged from 2,682 to 6,568,561 for male and 1,954 to 6,568,561 for female, while the number of cases ranged from 11 to 64,476 for male and 3 to 41,315 for female. Some articles did not report cohort size by sex. The follow-up period varied from 4 to 47 years. It should be noted that articles were counted more than once if they investigated multiple cancer types or reported results from multiple cohort studies. Further details on the characteristics of the studies can be found in Supplementary Material 1.
All studies included in the meta-analysis analyzed cancer risk according to alcohol consumption level, regardless of the specific cancer type. Light alcohol consumption was not significantly associated with all-cause cancer risk (RR, 1.02; 95% CI, 0.99 to 1.04). However, alcohol consumption levels from light to moderate (RR, 1.08; 95% CI, 1.04 to 1.12), moderate to heavy (RR, 1.19; 95% CI, 1.13 to 1.27), and heavy (RR, 1.39; 95% CI, 1.29 to 1.49) were each significantly associated with an increased risk of cancer. These findings confirm a dose-response relationship, where higher levels of alcohol consumption are linked to greater cancer risk (Figure 2). This is also supported by the linearity results of the dose-response meta-analysis (p for linearity < 0.001; data not shown). Additionally, females exhibited lower risks of all cancer types than males, and both males and females demonstrated a dose–response relationship between alcohol consumption and the risk of all cancer types (Supplementary Material 3).
We detected evidence of publication bias for heavy drinking (Egger’s test, p=0.01), as indicated by asymmetry in the funnel plot. However, it should be noted that for esophageal cancer, the calculation of a large risk value may have influenced the symmetry of the plot. There was no evidence of publication bias for other alcohol consumption levels (Supplementary Material 4).
Figure 3 shows the pooled RRs for each cancer type according to alcohol consumption level. Except for thyroid cancer, all other cancers showed a dose–response relationship with alcohol consumption, where the RR increased as the level of alcohol consumption increased. Heavy alcohol consumption was significantly associated with an elevated risk of all cancer types except thyroid cancer. Furthermore, light alcohol consumption was significantly associated with the risk of esophageal cancer (RR, 1.39; 95% CI, 1.10 to 1.75), colorectal cancer (RR, 1.04; 95% CI, 1.02 to 1.07), prostate cancer in male (RR, 1.05; 95% CI, 1.01 to 1.09), and breast cancer in female (RR, 1.05; 95% CI, 1.04 to 1.07). For light to moderate alcohol consumption, increased risks were evident for esophageal cancer (RR, 1.83; 95% CI, 1.40 to 2.40), colorectal cancer (RR, 1.09; 95% CI, 1.05 to 1.13), laryngeal cancer (RR, 1.63; 95% CI, 1.19 to 2.22), and breast cancer in female (RR, 1.12; 95% CI, 1.10 to 1.14). As the level of alcohol consumption increased to moderate to heavy, there were significant elevations in risk for esophageal (RR, 2.68; 95% CI, 2.15 to 3.35), stomach (RR, 1.20; 95% CI, 1.10 to 1.31), liver (RR, 1.14; 95% CI, 1.03 to 1.27), colorectal (RR, 1.20; 95% CI, 1.10 to 1.31), laryngeal (RR, 1.76; 95% CI, 1.11 to 2.78), prostate (RR, 1.11; 95% CI, 1.00 to 1.23), and breast cancers (RR, 1.23; 95% CI, 1.20 to 1.26). Heavy drinking was associated with an elevated risk for nearly all the evaluated cancers, with the exception of thyroid and laryngeal cancers.
The results of analysis stratified by sex are shown in Table 2. Light alcohol consumption was significantly associated with the risk of esophageal cancer in male and female (male: RR, 1.65, 95% CI, 1.36 to 1.99; female: RR, 1.17, 95% CI, 1.00 to 1.37). Moreover, the risk of colorectal cancer in male was associated with light alcohol consumption (RR, 1.16; 95% CI, 1.04 to 1.28). At moderate to heavy consumption levels, both male and female demonstrated heightened risks of cancer, with the exception of liver cancer, lung cancer, and pancreatic cancer in female. Heavy levels of alcohol consumption were found to elevate the risk of cancer for both male and female, except for colorectal and lung cancers in female. There was no evidence for publication bias for Esophageal, colorectal, lung, prostate, or breast cancer (except for light to moderate drinking) (Supplementary Material 5). Publication bias was not analyzed for other cancer types due to the limited number of studies [27].
This systematic review and meta-analysis aimed to examine the association between levels of alcohol consumption and cancer-specific risk. A total of 139 papers were included in the systematic review, and 106 papers were included in the subsequent meta-analysis. The analysis revealed a dose–response relationship, indicating that as alcohol consumption levels increased, the risk of cancer also increased for most cancer types. However, the impact of light alcohol consumption varied across cancer types. Significant associations were found between light alcohol consumption and esophageal, colorectal, prostate (in male), and breast (in female) cancers. Light to moderate drinking significantly elevated the risk of specific cancers, including esophageal, colorectal, laryngeal, and breast cancer (in female). Moderate and heavy drinking further escalated the risk, including for additional cancer types, including stomach, liver, and pancreatic cancers. Heavy drinking was associated with almost all evaluated cancers except for thyroid and laryngeal cancers. Furthermore, female generally had lower risks of all cancer types than male.
Our findings underscore the importance of introducing public health interventions and educational programs aimed at raising awareness about the heightened cancer risks linked to even modest levels of alcohol consumption. This is especially relevant concerning esophageal, colorectal, prostate (for male), and breast cancers (for female). As safe drinking limits for cancer risk have not been identified, it is crucial to develop appropriate interventions to address drinking behavior. The 2021 Korean National Cancer Prevention Awareness and Practice Survey showed that the guideline to “avoid alcohol consumption” was challenging for many respondents [28]. Furthermore, the percentage of respondents who adhered to the guideline by abstaining from alcohol declined from 76.2% in 2007 to 47.7% in 2021 [28]. From 2019 to 2020, the drinking rate of adults aged 19 and older in Korea was 74.8%, higher than the global average drinking rate of 43% (≥15 years) [29,30]. Although monthly drinking rates in Korea have decreased, over half of the population still consumes alcohol at least once a month [31]. Notably, around a quarter of these individuals consume 1 drink to 2 drinks per session [32]. Our findings showed that even light alcohol consumption, defined as less than 1 drink, was associated with increased risks of esophageal, colorectal, prostate (in male), and breast (in female) cancers. Apart from esophageal cancer, colorectal, prostate, and breast cancers rank among the top 5 most common cancers in Korea [33]. Given Korea’s high alcohol consumption rates, adhering to drinking guidelines might be an effective strategy to reduce the incidence of these cancers.
Our study results align with previous meta-analyses [11,19,34], indicating a dose–response relationship between alcohol consumption level and cancer risk. This consistency is further supported by a previous cohort study conducted in Korean male, which followed participants for 10.5 years and included repeated measurements of alcohol consumption [35]. Compared to non-drinkers, mild drinkers (< 15 g/day) exhibited a 4% increased risk, while medium-risk drinkers (15-30 g/day) and high-risk drinkers (≥ 30 g/day) experienced 14% and 28% increased risks, respectively [36].
In this study, light alcohol consumption was associated with a significantly higher risk of colorectal cancer and prostate cancer, with a significantly higher risk of colorectal cancer, especially in male. This finding is consistent with other previous studies. A previous study showed a significant dose–response relationship between low levels of alcohol consumption (> 1.33 g and < 25 g/day) and the prostate cancer risk [37]. In addition, Choi et al. [19] reported that light alcohol consumption slightly increased the incidence of colorectal cancer in males. A possible mechanism to explain this is that folic acid and acetaldehyde, which are present in alcoholic beverages, have been reported to promote colorectal carcinogenesis [38].
Our study revealed a strong association between esophageal cancer and alcohol consumption across all levels. This finding aligns with previous research by Bagnardi et al. [11], whose meta-analysis demonstrating a 30% increased risk of esophageal cancer, particularly squamous cell carcinoma, among individuals with light alcohol consumption (≤ 12.5 g/day; ≤ 1 drink/day). Notably, this risk was prominently observed in Asians (RR, 1.49; 95% CI, 1.12 to 1.98) [11], potentially due to genetic variations in ethanol metabolism [39]. Furthermore, another meta-analysis reported a significant increase in esophageal cancer risk at high alcohol consumption (100 g/day; RR, 4.23; 95% CI, 3.91 to 4.59) [40].
Our study found a strong association between breast cancer and alcohol consumption across all levels. Consistent with previous studies [41,42], even low levels of alcohol consumption were linked to an increased incidence of breast cancer. In a meta-analysis [42], it was observed that each additional 10 g of alcohol consumed per day increased the risk of breast cancer in female by 7.1% (95% CI, 5.5 to 8.7). Similarly, our study revealed that higher levels of alcohol consumption were associated with a higher risk of breast cancer in females. Notably, even very light alcohol consumption, defined as less than 0.5 drinks per day, increased the risk of breast cancer (RR, 1.04; 95% CI, 1.01 to 1.07) [19], indicating that there is no safe level of alcohol consumption in terms of increased risk of breast cancer. This heightened risk can be attributed to alcohol’s impact on the mammary gland, including elevating estrogen and insulin-like growth factor concentrations, altering structural development, and stimulating cell proliferation [43].
No significant association was found between thyroid cancer and any level of alcohol consumption, suggesting a potential protective role for alcohol. This finding is consistent with the results of 2 previous meta-analyses [19,44]. Alcohol consumption may play a preventive role in the development of thyroid cancer by reducing thyroid-stimulating hormone levels [45]. Additionally, alcohol might exert a direct toxic effect on thyroid cells, leading to a reduction in thyroid volume and a decreased risk of thyroid cancer [46]. However, due to the limited number of studies available on thyroid cancer, further research is warranted to confirm these findings.
In contrast, alcohol consumption has been identified as a risk factor for laryngeal cancer [11,19,47]. However, the available studies were insufficient to assess the association between heavy alcohol consumption and laryngeal cancer. Nonetheless, a moderate level of alcohol consumption was found to increase the risk of laryngeal cancer.
This study has several limitations that warrant acknowledgment. First, while a thorough assessment of literature quality indicated a low overall risk of bias, caution is needed in interpreting the findings because of the potential for bias and confounding effects. Second, variations in how different studies defined drinking levels could have introduced inconsistencies. For example, some studies did not distinguish between non-drinkers and former drinkers. This could have impacted the accuracy of the estimated effect size. Third, the type of alcoholic beverage (e.g., wine, beer, liquor) was not taken into account, although it is known that different types of alcohol may have varying effects on health outcomes. Fourth, since alcohol consumption is often self-reported, there is a possibility of recall bias influencing the effect size. Heavy drinkers might underreport their consumption, or individuals may underestimate their alcohol intake due to memory lapses [48,49]. Additionally, misclassifications and errors may arise from the use of different survey tools across the included studies. To address the issue of heterogeneity, a random-effects model was employed when high between-study heterogeneity was observed [27]. Lastly, we did not perform a stratified analysis of confounding factors to pinpoint potential sources of heterogeneity, so the results should be interpreted with caution.
Nonetheless, our study has several notable strengths. Firstly, we incorporated the most recent literature available in our review [21], ensuring that our review reflects the most up-to-date findings compared to previous meta-analyses conducted on this topic. Secondly, while previous meta-analyses primarily focused on exploring the association between specific doses of alcohol consumption and cancer risk, our study took a broader approach by investigating the association between various levels of alcohol consumption and cancer risk. This comprehensive analysis provides a more nuanced understanding of the topic. Lastly, we specifically aimed to include only cohort studies in our analysis, which provide stronger evidence for causal association.
Our findings support the proposal that higher levels of alcohol consumption are associated with an increased risk of cancer. Furthermore, even low levels of alcohol consumption have been found to elevate the risk of esophageal cancer, colorectal cancer, and breast cancer in females, as well as prostate and colorectal cancer in males. These findings suggest that there is no safe level of alcohol consumption in terms of cancer risk. In light of these findings, public health interventions, such as the strengthening of drinking guidelines, are necessary to mitigate the potential harm associated with alcohol consumption.
Supplementary materials are available at https://www.e-epih.org/.

Supplement Material 1.

Summary of studies characteristics by cancer types.

Supplement Material 2.

Summary of confounding factors by cancer type in selected literature.

Supplement Material 3.

All cancer and sex specific pooled RR estimates by meta-analysis.

Supplement Material 4.

Funnel plots of the meta-analysis of studies examining the relationship between all cancer and alcohol consumption levels.

Supplement Material 5.

Funnel plots of the meta-analysis of studies examining the relationship between cancer type and alcohol consumption levels.


The authors have no conflicts of interest to declare for this study.


This study was supported by the National R&D Program for Cancer Control through the National Cancer Center (NCC) funded by the Ministry of Health & Welfare, Republic of Korea (HA21C0142).


Conceptualization: Jun S, Park Hj, Park Hs. Data curation: Jun S, Park Hj, Kim UJ, Choi EJ. Formal analysis: Jun S, Park Hj. Methodology: Lee HA, Park B, Lee SY, Park Hs. Project administration: Lee HA, Park B, Lee SY, Jee S, Park Hs. Visualization: Jun S, Park Hj. Writing – original draft: Jun S, Park Hj, Kim UJ, Choi EJ, Lee HA, Park B, Lee SY, Jee S, Park Hs. Writing – review & editing: Park Hj, Jun S, Lee HA, Park B, Lee SY, Jee S, Park Hs.

The study was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) for the Ministry of Education and by the BK21 FOUR (Fostering Outstanding Universities for Research).
Figure 1.
Flow chart of study selection for inclusion in the meta-analysis.
Figure 2.
Pooled relative risks estimated by all cancer (esophageal; stomach; liver; pancreatic; colorectal; laryngeal; lung; thyroid; prostate; and breast) and alcohol consumption levels. The range of alcohol consumption levels was divided into light (0.01-12.4 g/day), light to moderate (12.5-24.9 g/day), moderate to heavy (25.0-49.9 g/day), and heavy (≥50.0 g/day). RR, relative risk; CI, confidence intervals; I2, indicates heterogeneity.
Figure 3.
Pooled RR estimated by cancer types and alcohol consumption levels. The range of alcohol consumption levels was divided into light (0.01-12.4 g/day), light to moderate (12.5-24.9 g/day), moderate to heavy (25.0-49.9 g/day), and heavy (≥50.0 g/day). RR, relative risk; CI, confidence intervals; I2, indicates heterogeneity; NA, not available.
Table 1.
Characteristics of studies included in the meta-analysis on cancer and alcohol consumption
Cancer type No. of studies Publication year
Cohort size (range)
Case size (range)
Age at baseline, range (yr) Year(s) of baseline, range Outcome (no. of studies) Duration of follow-up, range (yr)
Year No. of studies Geographical area No. of studies Male Female Male Female
Esophageal cancer 14 Before 2010 7 Asia 12 2,696-919,199 3,595-1,280,296 11-42,756 3-773 40-80 1965-2004 Death 10 5-20.8
Europe & Australia 1
After 2010 7 America 1 Incidence 4
Africa 0
Stomach cancer 14 Before 2010 6 Asia 10 2,696-919,199 3,595-1,280,296 64-3,452 44-821 18-66.6 1965-2004 Death 6 5-46
Europe & Australia 1
After 2010 8 America 3 Incidence 8
Africa 0
Liver cancer 10 Before 2010 3 Asia 8 2,696-919,199 3,595-1,280,296 36-3,807 19-3,807 20-66.6 1965-2003 Death 7 5-20.8
Europe & Australia 1
After 2010 7 America 1 Incidence 3
Africa 0
Pancreatic cancer 16 Before 2010 7 Asia 5 2,696-919,199 3,595-1,280,296 15-3,443 14-3,404 30-84 1972-2008 Death 6 5-24
Europe & Australia 5
After 2010 9 America 6 Incidence 10
Africa 0
Colorectal cancer 27 Before 2010 14 Asia 13 2,682-5,105,889 3,595-3,654,706 26-64,476 16-36,569 18-75 1972-2005 Death 9 5-30
Europe & Australia 7
After 2010 13 America 7 Incidence 18
Africa 0
Laryngeal cancer 2 Before 2010 1 Asia 1 919,199 1,280,296 49 138 48.3-55.9 1996-2001 Death 1 5-7.2
Europe & Australia 1
After 2010 1 America 0 Incidence 1
Africa 0
Lung cancer 20 Before 2010 11 Asia 6 4,265-6,568,561 4,265-6,568,561 70-10,227 75-10,227 18-84 1965-2008 Death 10 5-32.8
Europe & Australia 4
After 2010 9 America 10 Incidence 10
Africa 0
Thyroid cancer 5 Before 2010 3 Asia 0 55,040-292,101 69,153-1,280,296 170-172 169-421 41-62.55 1978-2001 Death 0 7.2-17.8
Europe & Australia 1
After 2010 2 America 4 Incidence 5
Africa 0
Prostate cancer 21 Before 2010 14 Asia 3 3,775-919,199 - 46-17,227 - 18-84 1971-2008 Death 5 4-46
Europe & Australia 5
After 2010 7 America 13 Incidence 16
Africa 0
Breast cancer 36 Before 2010 21 Asia 3 - 1,954-1,280,296 - 51-41,315 18-84 1959-2001 Death 5 1.99-28.5
Europe & Australia 13
After 2010 15 America 20 Incidence 31
Africa 0
Table 2.
Pooled relative risks by sex and cancer types1
Cancer type Sex Light
Light to moderate
Moderate to heavy
No. of studies RR (95% CI) No. of studies RR (95% CI) No. of studies RR (95% CI) No. of studies RR (95% CI)
Esophageal cancer Male 8 1.65 (1.36, 1.99) 8 1.88 (1.52, 2.34) 7 2.86 (2.45, 3.33) 11 3.94 (3.04, 5.10)
Female 2 1.17 (1.00, 1.37) 2 1.21 (1.02, 1.42) - - - - - -
Stomach cancer Male 4 1.00 (0.92, 1.08) 4 1.06 (0.96, 1.17) 4 1.19 (1.07, 1.33) 7 1.17 (1.03, 1.33)
Female 3 0.87 (0.58, 1.31) 2 1.02 (0.56, 1.87) - - - - - -
Liver cancer Male 2 0.93 (0.81, 1.06) 2 1.15 (0.65, 2.04) 2 1.12 (0.96, 1.31) 4 1.21 (1.12, 1.31)
Female 4 0.94 (0.75, 1.17) 3 1.25 (0.98, 1.57) - - - - - -
Pancreatic cancer Male 6 0.99 (0.89, 1.11) 5 1.05 (0.94, 1.17) 3 1.36 (1.19, 1.57) 8 1.28 (1.16, 1.41)
Female 4 0.91 (0.82, 0.99) 3 1.07 (0.97, 1.18) 2 1.15 (0.98, 1.36) 3 1.36 (1.15, 1.62)
Colorectal cancer Male 13 1.16 (1.04, 1.28) 11 1.14 (1.09, 1.20) 8 1.29 (1.23, 1.34) 12 1.55 (1.46, 1.66)
Female 11 1.00 (0.97, 1.04) 10 1.01 (0.78, 1.30) 4 1.07 (1.00, 1.14) 5 1.09 (0.79, 1.50)
Lung cancer Male 9 0.89 (0.85, 0.92) 8 0.90 (0.86, 0.94) 9 0.97 (0.93, 1.01) 8 1.11 (1.03, 1.20)
Female 8 0.93 (0.79, 1.09) 7 1.04 (0.98, 1.10) 6 1.00 (0.91, 1.10) 3 0.89 (0.66, 1.21)
Thyroid cancer2 Female 4 0.89 (0.77, 1.03) 3 0.67 (0.55, 0.82) - - - - - -

RR, relative risk; CI, confidence intervals.

1 The range of alcohol consumption levels was divided into light (0.01-12.4 g/day), light to moderate (12.5-24.9 g/day), moderate to heavy (25.0-49.9 g/day), and heavy (≥50.0 g/day).

2 Thyroid cancer (male) and laryngeal cancer were not presented because data from 1 or no study were obtained in this study, and information on sex-specific cancer incidence was insufficient.

  • 1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-249.ArticlePubMedPDF
  • 2. Rehm J, Gmel GE Sr, Gmel G, Hasan OS, Imtiaz S, Popova S, et al. The relationship between different dimensions of alcohol use and the burden of disease-an update. Addiction 2017;112:968-1001.ArticlePubMedPMCPDF
  • 3. Alcohol drinking. IARC Monogr Eval Carcinog Risks Hum 1988;44:1-378.PubMedPMC
  • 4. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Alcohol consumption and ethyl carbamate. IARC Monogr Eval Carcinog Risks Hum 2010;96:3-1383.PubMedPMC
  • 5. Cogliano VJ, Baan R, Straif K, Grosse Y, Lauby-Secretan B, El Ghissassi F, et al. Preventable exposures associated with human cancers. J Natl Cancer Inst 2011;103:1827-1839.ArticlePubMedPMC
  • 6. Rumgay H, Shield K, Charvat H, Ferrari P, Sornpaisarn B, Obot I, et al. Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study. Lancet Oncol 2021;22:1071-1080.ArticlePubMedPMC
  • 7. Di Castelnuovo A, Costanzo S, Bagnardi V, Donati MB, Iacoviello L, de Gaetano G. Alcohol dosing and total mortality in men and women: an updated meta-analysis of 34 prospective studies. Arch Intern Med 2006;166:2437-2445.ArticlePubMed
  • 8. Bagnardi V, Zambon A, Quatto P, Corrao G. Flexible meta-regression functions for modeling aggregate dose-response data, with an application to alcohol and mortality. Am J Epidemiol 2004;159:1077-1086.ArticlePubMed
  • 9. Ko H, Chang Y, Kim HN, Kang JH, Shin H, Sung E, et al. Low-level alcohol consumption and cancer mortality. Sci Rep 2021;11:4585.ArticlePubMedPMCPDF
  • 10. Gaziano JM, Gaziano TA, Glynn RJ, Sesso HD, Ajani UA, Stampfer MJ, et al. Light-to-moderate alcohol consumption and mortality in the Physicians’ Health Study enrollment cohort. J Am Coll Cardiol 2000;35:96-105.ArticlePubMed
  • 11. Bagnardi V, Rota M, Botteri E, Tramacere I, Islami F, Fedirko V, et al. Light alcohol drinking and cancer: a meta-analysis. Ann Oncol 2013;24:301-308.ArticlePubMed
  • 12. Rehm J, Shield KD. Alcohol use and cancer in the European Union. Eur Addict Res 2021;27:1-8.ArticlePubMedPDF
  • 13. Conigrave KM, Ali RL, Armstrong R, Chikritzhs TN, d’Abbs P, Harris MF, et al. Revision of the Australian guidelines to reduce health risks from drinking alcohol. Med J Aust 2021;215:518-524.ArticlePubMedPMCPDF
  • 14. European Commission. National low-risk drinking recommendations (or drinking guidelines) and standard units; 2022 [cited 2023 Feb 3]. Available from: https://knowledge4policy.ec.europa.eu/health-promotion-knowledge-gateway/national-low-risk-drinking-recommendations-drinking-guidelines_en.
  • 15. Boyle P, Autier P, Bartelink H, Baselga J, Boffetta P, Burn J, et al. European Code Against Cancer and scientific justification: third version (2003). Ann Oncol 2003;14:973-1005.ArticlePubMed
  • 16. Scoccianti C, Cecchini M, Anderson AS, Berrino F, Boutron-Ruault MC, Espina C, et al. European Code against Cancer 4th Edition: alcohol drinking and cancer. Cancer Epidemiol 2016;45:181-188.ArticlePubMed
  • 17. National Cancer Information Center. Cancer prevention program; 2023 [cited 2023 Nov 22]. Available from: https://www.cancer.go.kr/lay1/S1T549C551/contents.do (Korean).
  • 18. Myung SK. Erroneous conclusions about the association between light alcohol drinking and the risk of cancer: comments on Bagnardi et al.’s meta-analysis. Ann Oncol 2016;27:2138.ArticlePMC
  • 19. Choi YJ, Myung SK, Lee JH. Light alcohol drinking and risk of cancer: a meta-analysis of cohort studies. Cancer Res Treat 2018;50:474-487.ArticlePubMedPDF
  • 20. International Agency for Research on Cancer. World cancer report 2014. [cited 2023 Jan 31]. Available from: https://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014.
  • 21. Jung KJ, Baek JW, Shin SY, Jee SH. Genetically determined alcohol consumption and cancer risk in Korea. Epidemiol Health 2023;45:e2023077.ArticlePubMedPMC
  • 22. Patra J, Taylor B, Irving H, Roerecke M, Baliunas D, Mohapatra S, et al. Alcohol consumption and the risk of morbidity and mortality for different stroke types--a systematic review and meta-analysis. BMC Public Health 2010;10:258.ArticlePubMedPMCPDF
  • 23. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis; 2021 [cited 2023 Jan 31]. Available from: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
  • 24. Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). [cited 2023 Feb 2]. Available from: http://handbook-5-1.cochrane.org/.
  • 25. Shim SR, Lee J. Dose-response meta-analysis: application and practice using the R software. Epidemiol Health 2019;41:e2019006.ArticlePubMedPMC
  • 26. Pustejovsky JE, Rodgers MA. Testing for funnel plot asymmetry of standardized mean differences. Res Synth Methods 2019;10:57-71.ArticlePubMedPDF
  • 27. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011;343:d4002.ArticlePubMed
  • 28. Oh JK, Park E, Kim B, Choi YJ, Yun EH, Lim MK, et al. Awareness of and practice toward cancer prevention recommendations: results of the Korean national cancer prevention awareness and practice survey in 2021. Epidemiol Health 2022;44:e2022068.ArticlePubMedPMCPDF
  • 29. Lee S, Kim J, Kim JS. Current status of Korean alcohol drinking in accordance with the Korean alcohol guidelines for moderate drinking based on facial flushing. Korean J Fam Med 2023;44:129-142.ArticlePubMedPMCPDF
  • 30. World Health Organization. Global status report on alcohol and health 2018. [cited 2023 Aug 10]. Available from: https://www.who.int/publications/i/item/9789241565639.
  • 31. Korea Centers for Disease Control and Prevention. 2021 Korea national health statistics. Cheongju: Korea Centers for Disease Control and Prevention; 2022. p 63-71 (Korean).
  • 32. Yeo E, Shin JD, Lee BJ, Woo SH, Han GY, Jung DW, et al. The 2020 Korea Welfare Panel Study (KoWePS): a descriptive report. [cited 2023 Aug 16]. Available from: https://repository.kihasa.re.kr/handle/201002/37405 (Korean).
  • 33. National Cancer Information Center. Cancer incidence, by type of cancer; 2023 [cited 2023 Nov 22]. Available from: https://www.cancer.go.kr/lay1/S1T639C641/contents.do (Korean).
  • 34. Stockwell T, Zhao J, Panwar S, Roemer A, Naimi T, Chikritzhs T. Do “moderate” drinkers have reduced mortality risk? A systematic review and meta-analysis of alcohol consumption and allcause mortality. J Stud Alcohol Drugs 2016;77:185-198.ArticlePubMedPMC
  • 35. Bui TT, Han M, Luu NM, Tran TP, Lim MK, Oh JK. Cancer risk according to alcohol consumption trajectories: a population-based cohort study on 2.8 million Korean men. J Epidemiol 2023;doi: https://doi.org/10.2188/jea.JE20220175.Article
  • 36. Yoo JE, Shin DW, Han K, Kim D, Jeong SM, Koo HY, et al. Association of the frequency and quantity of alcohol consumption with gastrointestinal cancer. JAMA Netw Open 2021;4:e2120382.ArticlePubMedPMC
  • 37. Zhao J, Stockwell T, Roemer A, Chikritzhs T. Is alcohol consumption a risk factor for prostate cancer? A systematic review and meta-analysis. BMC Cancer 2016;16:845.ArticlePubMedPMCPDF
  • 38. Johnson CH, Golla JP, Dioletis E, Singh S, Ishii M, Charkoftaki G, et al. Molecular mechanisms of alcohol-induced colorectal carcinogenesis. Cancers (Basel) 2021;13:4404.ArticlePubMedPMC
  • 39. Goedde HW, Agarwal DP, Fritze G, Meier-Tackmann D, Singh S, Beckmann G, et al. Distribution of ADH2 and ALDH2 genotypes in different populations. Hum Genet 1992;88:344-346.ArticlePubMedPDF
  • 40. Bagnardi V, Blangiardo M, La Vecchia C, Corrao G. Alcohol consumption and the risk of cancer: a meta-analysis. Alcohol Res Health 2001;25:263-270.PubMedPMC
  • 41. Chen WY, Rosner B, Hankinson SE, Colditz GA, Willett WC. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. JAMA 2011;306:1884-1890.ArticlePubMedPMC
  • 42. Hamajima N, Hirose K, Tajima K, Rohan T, Calle EE, Heath CW Jr, et al. Alcohol, tobacco and breast cancer—collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer 2002;87:1234-1245.ArticlePubMedPMCPDF
  • 43. Singletary KW, Gapstur SM. Alcohol and breast cancer: review of epidemiologic and experimental evidence and potential mechanisms. JAMA 2001;286:2143-2151.ArticlePubMed
  • 44. Hong SH, Myung SK, Kim HS; Korean Meta-Analysis (KORMA) Study Group. Alcohol intake and risk of thyroid cancer: a meta-analysis of observational studies. Cancer Res Treat 2017;49:534-547.ArticlePubMedPDF
  • 45. Zoeller RT, Fletcher DL, Simonyl A, Rudeen PK. Chronic ethanol treatment reduces the responsiveness of the hypothalamic-pituitary-thyroid axis to central stimulation. Alcohol Clin Exp Res 1996;20:954-960.ArticlePubMed
  • 46. Valeix P, Faure P, Bertrais S, Vergnaud AC, Dauchet L, Hercberg S. Effects of light to moderate alcohol consumption on thyroid volume and thyroid function. Clin Endocrinol (Oxf) 2008;68:988-995.ArticlePubMed
  • 47. Islami F, Tramacere I, Rota M, Bagnardi V, Fedirko V, Scotti L, et al. Alcohol drinking and laryngeal cancer: overall and dose-risk relation--a systematic review and meta-analysis. Oral Oncol 2010;46:802-810.ArticlePubMed
  • 48. Ekholm O. Influence of the recall period on self-reported alcohol intake. Eur J Clin Nutr 2004;58:60-63.ArticlePubMedPDF
  • 49. Heeb JL, Gmel G. Measuring alcohol consumption: a comparison of graduated frequency, quantity frequency, and weekly recall diary methods in a general population survey. Addict Behav 2005;30:403-413.ArticlePubMed

Figure & Data



    Citations to this article as recorded by  
    • Exploring genetic associations of Crohn’s disease and ulcerative colitis with extraintestinal cancers in European and East Asian populations
      Chengdong Yu, Jiawei Xu, Siyi Xu, Lei Tang, Qinyuan Han, Xiaoqiang Zeng, Yanxiao Huang, Tenghua Yu, Zhengkui Sun
      Frontiers in Immunology.2024;[Epub]     CrossRef

    Related articles

    Epidemiol Health : Epidemiology and Health